Noninvasive brain stimulation for major depressive disorder
Brain Oscillation Synchronized Stimulation of the Frontal Cortex: Randomized Controlled Trial Comparing Frontal Theta-oscillation Synchronized Repetitive TMS With Standard TMS in Major Depressive Disorder
This study is testing a new brain stimulation method to see if it can help people with major depressive disorder feel better compared to standard treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University Hospital Tuebingen Academic / other |
| Locations | 1 site (Tuebingen, Baden-Wuerttemberg) |
| Trial ID | NCT06345651 on ClinicalTrials.gov |
What this trial studies
This study investigates a novel non-invasive brain stimulation method aimed at alleviating symptoms of major depressive disorder (MDD) by targeting dysfunctional brain oscillations. It employs EEG-triggered transcranial magnetic stimulation (TMS) to synchronize stimulation with specific brain activity patterns. The trial is designed as a double-blind randomized controlled pilot study, comparing the effects of theta-synchronized TMS over the dorsomedial prefrontal cortex with standard TMS therapy. The primary outcome will be measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) to assess changes in depressive symptoms.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 who meet DSM-5 criteria for major depressive disorder and have experienced treatment resistance to previous antidepressant medications.
Not a fit: Patients who do not meet the criteria for major depressive disorder or those who have not previously failed antidepressant treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a more effective treatment option for patients with major depressive disorder who have not responded to traditional pharmacological therapies.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating potential efficacy in treating major depressive disorder.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects have to be 18 to 65 years old * Subjects meet DSM-5 criteria for current major depressive disorder (MDD), confirmed with the Structured Clinical Interview for DSM-5. * Subjects score 20 points or more on the Montgomery-Åsberg Depression Rating Scale (MADRS). * Subjects must have had at least one non-response (meaning a failure to achieve remission) in a previous pharmacological antidepressant treatment trial of sufficient (meaning a doses considered to be effective (e.g., superior to placebo in controlled clinical trials) and the duration needs to be sufficient to produce a ro-bust therapeutic effect (e.g., 12 weeks)) dosage and duration as assessed by the ATHF; treatment failure can be for the current or any prior depressive episode; medication resistance for the current episode is not required. * Subject is in good physical and mental health. Subject understands the study procedures and agrees to participate in the study by giving written informed consent. * Subject is willing to comply with the study restrictions. * If antidepressant medication is being taken, it has to be taken for at least 2 weeks before inclusion in the study and the dose or active substance must not have been changed. It is necessary that no change in medication will be made until the end of the study (last visit takes place 4 weeks after the last therapy session). If a change in medication is necessary, further study participation is no longer possible. Exclusion Criteria: * Subject is under the age of legal consent. * Subject has a diagnosis of bipolar disorder. * Subject suffers from current symptoms of psychosis. * Subject has active suicidal ideation with plan and/or intent. * A current major depressive episode longer than 5 years. * Subject has a history of substance abuse or dependence within the past 2 years. * Subject has a diagnosis of antisocial or borderline personality disorder. * Subject suffers from other major psychiatric or medical comorbidity * Subject has a history of seizure disorder * Subject has a history of severe head injury with loss of consciousness. * Subject had a prior brain surgery * Subjects with intake of pro-convulsive medication, e.g. imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, MDMA (ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline, in accord with present consensus guidelines on safety, ethical considerations, and application of TMS in clinical practice and research. * Daily intake of Benzodiazepines other than Lorazepam \>1 mg/d * Subject has a cardiac pacemaker, implanted medication pump, intracardiac line, or acute, unstable cardiac disease. * Subject has an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head (excluding the mouth) that cannot be safely removed. * Subject has participated in another study within 2 weeks prior to the first study visit. * Subject has contra-indications to MRI scans or does not agree that (1) the scans are obtained for research purposes only and will not be evaluated by a qualified neuroradiologist; if an abnormality is present, this may well not be noticed by the doctors, scientists and other staff involved in the study and handling the MRI da-ta; and that (2) if any of the staff involved in the study do suspect a relevant ab-normality to be present in any of the scans, they will reveal this to the subject so that a further diagnostic workup can be conducted outside of the study. * Subject is pregnant or trying to get pregnant. If someone is not sure weather she is pregnant or not we will test HCG in the urine. * Planned or anticipated changes of medication within the study period. If a change in medication is necessary, further study participation is no longer possible.
Where this trial is running
Tuebingen, Baden-Wuerttemberg
- University Hospital Tuebingen — Tuebingen, Baden-Wuerttemberg, Germany (Recruiting)
Study contacts
- Study coordinator: Anne Lieb, Dr.
- Email: anne.lieb@uni-tuebingen.de
- Phone: +4970712980483
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.